top of page
  • Recruiting

NCT03941860: Phase 3 - EAA171 - OPTIMUM - Addition of Ixazomib to Lenalidomide in Residual Myeloma

Updated: Oct 4, 2022


EAA171

OPTIMUM

NCT03941860: Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

EAA171 optimum myeloma study ecog acrin

Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

NCT03941860: Phase 3 - Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial


This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.


Sponsor

National Cancer Institute (NCI)


ECOG-ACRIN Cancer Research Group

 

ClinicalTrials.gov Identifier: NCT03941860

Official Title: Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)

First Posted : May 8, 2019

Click here for details on ClinicalTrials.Gov


EAA171 / OPTIMUM Home Page - ECOG-ACRIN Cancer Research Group

 

Ixazomib: National Cancer Institute

Ixazomib: MedlinePlus Drug Information